


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-1.43%
-0.66%
-3.56%
CRMD
CorMedix
$6.40
Strengths

Expands stock buyback program

Upgraded on attractively valued

Investors confidence is positive
Risk Analysis

Earnings are forecast to decrease
CRMD Price Performance
$7.34 (-12.81%)
$11.49 (-44.30%)
$10.17 (-37.07%)
$6.74 (-5.04%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings
Reported a weak earnings
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Expands stock buyback program
Investors confidence is positive
Future
Future
Earnings are forecast to decrease
CRMD Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
CRMD Street Sentiment is unimpressive and have negative views on the near-term outlook
CRMD has Medium risk level
Risk Indicators
Sentiments overview associated with events and the stock performance
Average key support and resistance price levels
Recent Upgrades and Downgrades
Dec 19, 2025
Reiterate
Buy
D. Boral Capital
Dec 08, 2025
Upgrade
Buy
Zacks
Nov 14, 2025
Reiterate
Buy
HC Wainwright & Co.
Nov 13, 2025
Reiterate
Buy
D. Boral Capital
Nov 13, 2025
Reiterate
Buy
Needham
TLPH
Talphera Inc.
0.81
-8.86%
MIRM
Mirum Pharmaceutical
89.78
-2.15%
What is CRMD current stock price?
What are CRMD stock strengths?
What is CRMD Risk Level?
What is CRMD market cap and volume?
What is CRMD current Stock IQ?
Should I buy CRMD stock right now?
Is CRMD a Strong Buy right now?
What does a 'Strong Buy' rating mean for CRMD?
What does a 'Strong Sell' rating mean for CRMD?
What factors influence CRMD's Stock IQ?
Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
CRMD
CorMedix
Current Price
$6.40
Runners Also Watch
TLPH
Talphera Inc.
0.81
-8.86%
MIRM
Mirum Pharmaceutical
89.78
-2.15%

CRMD Price Performance
$7.34 (-12.81%)
$11.49 (-44.30%)
$10.17 (-37.07%)
$6.74 (-5.04%)
CRMD Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings
Reported a weak earnings
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Expands stock buyback program
Investors confidence is positive
Future
Future
Earnings are forecast to decrease
CRMD Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
CRMD Street Sentiment is unimpressive and have negative views on the near-term outlook
CRMD has Medium risk level
Risk Indicators
Average key support and resistance price levels
Overall Wall Street Rating
CRMD Stock IQ
Stock Insights
Strengths

Expands stock buyback program

Upgraded on attractively valued

Investors confidence is positive
Risk Analysis

Earnings are forecast to decrease
CRMD Latest Analysis
Leerink cuts CorMedix stock price target on expense adjustments.
Fri Mar 6, 2026
CorMedix Q4 Revenue Improves. Reaffirms FY26 Outlook. Plans To Report Phase III REZZAYO Data In Q2 . (RTTNews) - CorMedix Inc. (CRMD) a biopharmaceutical company announced financial results for the fourth quarter and full-year 2025 with revenue growth. In addition the firm reaffirmed full-year 2026 guidance.
Fri Mar 6, 2026
CorMedix reports mixed Q4 results. reaffirms FY26 outlook.
Thu Mar 5, 2026
CorMedix nears an 11-month low after earnings miss.
Thu Mar 5, 2026
Cormedix Earnings Preview.
Cormedix (NASDAQ:CRMD) is gearing up to announce its quarterly earnings on Thursday 2026-03-05. Here'.s a quick overview of what investors should know before the release.
Analysts are estimating that Cormedix will report an earnings per share (EPS) of $0.83.
The market awaits Cormedix'.s announcement with hopes high for news of surpassing estimates and providing upbeat guid
Wed Mar 4, 2026
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
CRMD Stock trends
CRMD Stock performance
CRMD Stock analysis
CRMD investment strategies
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.